Developer docs
API playgroundTry for free, no card

Search company profiles

Humane Genomics

Full company profile

uuid0002why

Namestring
Humane Genomics
Legal namestring
Humane Genomics Inc.
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Humane Genomics is a privately held, pre-clinical biotechnology company founded in 2019 and headquartered in New York City. The company engineers synthetic oncolytic RNA viruses, based on a Vesicular Stomatitis Virus (VSV) chassis, as targeted cancer therapeutics. Its lead candidate, HGI627, targets hepatoblastoma and pediatric liver cancer using a two-factor authentication approach: a retargeted glycoprotein that infects only cancer cells overexpressing GPC3, combined with a CTNNB1-responsive aptazyme ON-switch that restricts viral replication to cancer cells carrying the target protein.

The company's core asset is an Artificial Virus Platform that integrates computer-aided DNA design, DNA synthesis, and a proprietary virus boot-up protocol to enable rapid design-build-test cycles on engineered oncolytic viruses. Supporting technologies include an Aptazyme Platform for RNA-based replication control and Glycoprotein Engineering libraries for retargeting viral tropism. The platform has demonstrated a 73% design-to-validated-DNA success rate, >70% virus boot-up success (improved from <1% in published literature), and turnaround from design to testable virus in under three weeks. Preclinical data show >99.9% tumor reduction with a single intraperitoneal dose in Hep3B xenograft models and tolerability at doses 300x higher than the anticipated clinical starting dose.

The business model targets eventual commercialization of proprietary oncolytic viral therapies through clinical and pharmaceutical distribution channels following regulatory approval, supplemented by potential platform licensing and co-development partnerships. The company is currently advancing HGI627 toward First-in-Human trials in collaboration with Texas Children's Hospital and cGMP manufacturing partner Genezen. Revenue has not been disclosed and the company is pre-revenue, having raised a $4M Series Seed led by Union Square Ventures in February 2025 to fund manufacturing and preclinical activities.

Short descriptiontext

Humane Genomics is a pre-clinical biotech that engineers synthetic oncolytic RNA viruses (VSV-based) as precision cancer therapeutics, with lead candidate HGI627 targeting pediatric liver cancer via a two-factor authentication platform combining retargeted glycoproteins and aptazyme-controlled replication.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncolytic viral therapy, synthetic virology platform, RNA virus engineering, cancer therapeutics development, viral vector design
Industry2 codes
PRIMARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oncolytic Virotherapy / Cancer Therapeutics
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Oncolytic Viral Therapy Development and Clinical Commercialization
TypeOne Time License
Description

Humane Genomics is a pre-clinical stage biotech company developing engineered oncolytic RNA viruses (based on VSV) as cancer therapeutics. The primary business model is developing and commercializing novel cancer therapies, with initial focus on pediatric liver cancer (hepatoblastoma, HGI627). Revenue will be derived from therapeutic product sales following regulatory approval.

humanegenomics.com
2Platform Licensing and Partnership Deals
TypeLicensing Royalties
Description

The company may generate revenue through licensing its synthetic virus engineering platform to other biotech or pharmaceutical companies, and through co-development partnerships.

humanegenomics.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Humane Genomics develops engineered oncolytic RNA viruses as precision cancer therapeutics using a proprietary synthetic virology platform. Its lead candidate HGI627 is a Vesicular Stomatitis Virus engineered with two-factor authentication (GPC3-targeted glycoprotein entry plus a CTNNB1-responsive aptazyme replication ON-switch) for hepatoblastoma and pediatric liver cancer. The platform combines computer-aided virus design, a digital library of validated components, and optimized boot-up protocols to compress design-to-testable-virus timelines to under three weeks.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • >99.9% tumor reduction with a single IP dose of HGI627 in Hep3B xenograft models, with residual cells confirmed apoptotic
+6 more records
Product overview1 text field

Humane Genomics is a biotech company developing precision-engineered oncolytic viral therapies for cancer treatment. The company's core offering is its Artificial Virus Platform—a synthetic biology platform that enables rapid design, assembly, and testing of oncolytic RNA viruses. The platform incorporates two key technologies: a Glycoprotein Engineering system for selective infection (retargeting viral entry to cancer cells) and an Aptazyme Platform for selective replication (using RNA-based switches to control viral replication based on cancer-specific proteins). Lead product candidate HGI627 targets hepatoblastoma and pediatric liver cancer using a two-factor authentication approach combining GPC3-targeted infection with CTNNB1-responsive replication control. Additional pipeline candidates include HGI536 for proof-of-concept demonstration.

Product and service2 records
1HGI627
CategoryOncolytic Virotherapy / Lead Therapeutic Candidate
Description

Lead oncolytic virus candidate of Humane Genomics engineered for hepatoblastoma and pediatric liver cancer. Built on Vesicular Stomatitis Virus (VSV) with two-factor authentication: a retargeted glycoprotein for tumor-specific infection targeting GPC3, combined with a CTNNB1-responsive aptazyme replication ON-switch. Demonstrated complete response in Hep3B xenografts with a single systemic dose in preclinical studies and is advancing toward cGMP manufacturing and First-in-Human (FIH) trials.

2HGI536
CategoryOncolytic Virotherapy / Preclinical Prototype Candidate
Description

Prototype oncolytic VSV virus carrying a CTNNB1-responsive aptazyme placed in the untranslated region of an essential VSV gene. Used as proof-of-concept to demonstrate selective replication functionality, showing robust cytotoxicity in CTNNB1-positive cells and no detectable cytotoxicity in CTNNB1 knockout cells.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2025-11-12
Description

Manufacturing partnership for process transfer and cGMP (Current Good Manufacturing Practice) manufacturing of Humane Genomics' lead oncolytic virus candidate (HGI627) for hepatoblastoma (pediatric liver cancer). Genezen is a leading viral vector CDMO with facilities in Indianapolis and Lexington. The collaboration will produce cGMP-grade batches suitable for toxicology studies and ultimately First-in-Human (FIH) trials, pending regulatory approval. Tech transfer and proof-of-concept runs will be completed over the coming months.

2Alexandria LaunchLabs
Strategic tierCoreTypeOthersAnnounced on2025-07-03
Description

Humane Genomics relocated its laboratory from BioLabs@NYU Langone to Alexandria LaunchLabs, a leading life sciences innovation space in New York City. The new location provides expanded lab infrastructure, shared resources, a vivarium for in-house mouse studies, and proximity to an ecosystem of emerging biotech companies and strategic partners.

humanegenomics.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical research collaboration for hepatoblastoma and pediatric liver cancer therapy development. The partnership involves co-development of HGI627 and planning for clinical trials. Dr. Sanjeev Vasudevan from Texas Children's served as sponsor for AACR abstract submissions.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Clinical-stage oncology company developing a proprietary platform of engineered oncolytic viruses (RP1, RP2, RP3) for solid tumors. Highly comparable in modality (engineered OV), strategy (platform-based), and customer (oncology), though more advanced (public, mid-stage trials) and based on HSV rather than VSV.

TypeDirect peer
Description

Develops oncolytic virus therapies derived from vesicular stomatitis virus and measles virus, with a similar platform-engineering approach to Humane Genomics. Direct overlap in VSV-based oncolytic modality and solid tumor focus.

TypeDirect peer
Description

Clinical-stage biotech developing pelareorep, a systemically delivered oncolytic reovirus for solid tumors and hematological malignancies. Comparable as a systemically administered engineered OV platform targeting multiple tumor types.

TypeDirect peer
Description

Develops oncolytic vaccinia virus therapies (e.g., GL-ONC1) for solid tumors. Direct peer in the engineered oncolytic virus space with similar two-pronged strategy of intravenous/systemic delivery and tumor selectivity.

5Istari Oncology
TypeDirect peer
Description

Clinical-stage company developing PVSRIPO, an engineered poliovirus-based oncolytic immunotherapy for solid tumors (notably glioblastoma). Comparable as an engineered, tumor-targeted viral therapy advancing through oncology clinical trials.

TypeEmerging player
Description

Develops oncolytic adenoviruses engineered to express cytokines for solid tumor treatment. Comparable as a platform-based engineered oncolytic virus company, though focused on adenovirus and cytokine-armoring rather than selective replication.

7Turnstone Biologics
TypeEmerging player
Description

Develops next-generation viral immunotherapies including oncolytic viruses and cancer vaccines. Adjacent peer in the engineered virus-for-cancer modality, with overlap in synthetic virology approaches to oncology.

TypeBroad incumbent
Description

Large biopharmaceutical company with the only FDA-approved oncolytic virus therapy (talimogene laherparepvec / Imlygic for melanoma). Sets the competitive and regulatory benchmark for the engineered OV field in which Humane Genomics operates.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Humane Genomics

Oncolytic Virotherapy / Cancer Therapeuticshumanegenomics.com

Humane Genomics is a pre-clinical biotech that engineers synthetic oncolytic RNA viruses (VSV-based) as precision cancer therapeutics, with lead candidate HGI627 targeting pediatric liver cancer via a two-factor authentication platform combining retargeted glycoproteins and aptazyme-controlled replication.

What Humane Genomics does

Humane Genomics is a privately held, pre-clinical biotechnology company founded in 2019 and headquartered in New York City. The company engineers synthetic oncolytic RNA viruses, based on a Vesicular Stomatitis Virus (VSV) chassis, as targeted cancer therapeutics. Its lead candidate, HGI627, targets hepatoblastoma and pediatric liver cancer using a two-factor authentication approach: a retargeted glycoprotein that infects only cancer cells overexpressing GPC3, combined with a CTNNB1-responsive aptazyme ON-switch that restricts viral replication to cancer cells carrying the target protein.

The company's core asset is an Artificial Virus Platform that integrates computer-aided DNA design, DNA synthesis, and a proprietary virus boot-up protocol to enable rapid design-build-test cycles on engineered oncolytic viruses. Supporting technologies include an Aptazyme Platform for RNA-based replication control and Glycoprotein Engineering libraries for retargeting viral tropism. The platform has demonstrated a 73% design-to-validated-DNA success rate, >70% virus boot-up success (improved from <1% in published literature), and turnaround from design to testable virus in under three weeks. Preclinical data show >99.9% tumor reduction with a single intraperitoneal dose in Hep3B xenograft models and tolerability at doses 300x higher than the anticipated clinical starting dose.

The business model targets eventual commercialization of proprietary oncolytic viral therapies through clinical and pharmaceutical distribution channels following regulatory approval, supplemented by potential platform licensing and co-development partnerships. The company is currently advancing HGI627 toward First-in-Human trials in collaboration with Texas Children's Hospital and cGMP manufacturing partner Genezen. Revenue has not been disclosed and the company is pre-revenue, having raised a $4M Series Seed led by Union Square Ventures in February 2025 to fund manufacturing and preclinical activities.

Humane Genomics firmographics

Firmographics
Name
Humane Genomics
Legal name
Humane Genomics Inc.
Website
https://humanegenomics.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
Humane Genomics is a pre-clinical biotech that engineers synthetic oncolytic RNA viruses (VSV-based) as precision cancer therapeutics, with lead candidate HGI627 targeting pediatric liver cancer via a two-factor authentication platform combining retargeted glycoproteins and aptazyme-controlled replication.
Ownership category
akta.pro rank

Humane Genomics industry classification

Industry
Product category
Oncolytic Virotherapy / Cancer Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Oncolytic viral therapy
  • Synthetic virology platform
  • RNA virus engineering
  • Cancer therapeutics development
  • Viral vector design

Where Humane Genomics is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Humane Genomics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Oncolytic Viral Therapy Development and Clinical Commercialization: Humane Genomics is a pre-clinical stage biotech company developing engineered oncolytic RNA viruses (based on VSV) as cancer therapeutics. The primary business model is developing and commercializing novel cancer therapies, with initial focus on pediatric liver cancer (hepatoblastoma, HGI627). Revenue will be derived from therapeutic product sales following regulatory approval.
  2. Platform Licensing and Partnership Deals: The company may generate revenue through licensing its synthetic virus engineering platform to other biotech or pharmaceutical companies, and through co-development partnerships.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Humane Genomics product offering

Product offering

Core offering

Humane Genomics develops engineered oncolytic RNA viruses as precision cancer therapeutics using a proprietary synthetic virology platform. Its lead candidate HGI627 is a Vesicular Stomatitis Virus engineered with two-factor authentication (GPC3-targeted glycoprotein entry plus a CTNNB1-responsive aptazyme replication ON-switch) for hepatoblastoma and pediatric liver cancer. The platform combines computer-aided virus design, a digital library of validated components, and optimized boot-up protocols to compress design-to-testable-virus timelines to under three weeks.

Product overview

Humane Genomics is a biotech company developing precision-engineered oncolytic viral therapies for cancer treatment. The company's core offering is its Artificial Virus Platform—a synthetic biology platform that enables rapid design, assembly, and testing of oncolytic RNA viruses. The platform incorporates two key technologies: a Glycoprotein Engineering system for selective infection (retargeting viral entry to cancer cells) and an Aptazyme Platform for selective replication (using RNA-based switches to control viral replication based on cancer-specific proteins). Lead product candidate HGI627 targets hepatoblastoma and pediatric liver cancer using a two-factor authentication approach combining GPC3-targeted infection with CTNNB1-responsive replication control. Additional pipeline candidates include HGI536 for proof-of-concept demonstration.

Differentiator

Problem solved

Functional benefit

Products and services

  • HGI627 Lead oncolytic virus candidate of Humane Genomics engineered for hepatoblastoma and pediatric liver cancer. Built on Vesicular Stomatitis Virus (VSV) with two-factor authentication: a retargeted glycoprotein for tumor-specific infection targeting GPC3, combined with a CTNNB1-responsive aptazyme replication ON-switch. Demonstrated complete response in Hep3B xenografts with a single systemic dose in preclinical studies and is advancing toward cGMP manufacturing and First-in-Human (FIH) trials.
  • HGI536 Prototype oncolytic VSV virus carrying a CTNNB1-responsive aptazyme placed in the untranslated region of an essential VSV gene. Used as proof-of-concept to demonstrate selective replication functionality, showing robust cytotoxicity in CTNNB1-positive cells and no detectable cytotoxicity in CTNNB1 knockout cells.

Quantifiable outcome

  • >99.9% tumor reduction with a single IP dose of HGI627 in Hep3B xenograft models, with residual cells confirmed apoptotic
  • +6 more outcomes

Companies that use Humane Genomics

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Humane Genomics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Humane Genomics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • GenezencoreImplementation/ SI/ Consulting Partner · 12 November 2025Manufacturing partnership for process transfer and cGMP (Current Good Manufacturing Practice) manufacturing of Humane Genomics' lead oncolytic virus candidate (HGI627) for hepatoblastoma (pediatric liver cancer). Genezen is a leading viral vector CDMO with facilities in Indianapolis and Lexington. The collaboration will produce cGMP-grade batches suitable for toxicology studies and ultimately First-in-Human (FIH) trials, pending regulatory approval. Tech transfer and proof-of-concept runs will be completed over the coming months.
  • Alexandria LaunchLabscoreOthers · 3 July 2025Humane Genomics relocated its laboratory from BioLabs@NYU Langone to Alexandria LaunchLabs, a leading life sciences innovation space in New York City. The new location provides expanded lab infrastructure, shared resources, a vivarium for in-house mouse studies, and proximity to an ecosystem of emerging biotech companies and strategic partners.
  • Texas Children's HospitalcoreStrategic or Co-development PartnerClinical research collaboration for hepatoblastoma and pediatric liver cancer therapy development. The partnership involves co-development of HGI627 and planning for clinical trials. Dr. Sanjeev Vasudevan from Texas Children's served as sponsor for AACR abstract submissions.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Humane Genomics competitors and assessment

Company assessment

Direct peers

  • Replimune Group: Clinical-stage oncology company developing a proprietary platform of engineered oncolytic viruses (RP1, RP2, RP3) for solid tumors. Highly comparable in modality (engineered OV), strategy (platform-based), and customer (oncology), though more advanced (public, mid-stage trials) and based on HSV rather than VSV.
  • Vyriad: Develops oncolytic virus therapies derived from vesicular stomatitis virus and measles virus, with a similar platform-engineering approach to Humane Genomics. Direct overlap in VSV-based oncolytic modality and solid tumor focus.
  • Oncolytics Biotech: Clinical-stage biotech developing pelareorep, a systemically delivered oncolytic reovirus for solid tumors and hematological malignancies. Comparable as a systemically administered engineered OV platform targeting multiple tumor types.
  • Genelux Corporation: Develops oncolytic vaccinia virus therapies (e.g., GL-ONC1) for solid tumors. Direct peer in the engineered oncolytic virus space with similar two-pronged strategy of intravenous/systemic delivery and tumor selectivity.
  • Istari Oncology: Clinical-stage company developing PVSRIPO, an engineered poliovirus-based oncolytic immunotherapy for solid tumors (notably glioblastoma). Comparable as an engineered, tumor-targeted viral therapy advancing through oncology clinical trials.

Emerging players

  • TILT Biotherapeutics: Develops oncolytic adenoviruses engineered to express cytokines for solid tumor treatment. Comparable as a platform-based engineered oncolytic virus company, though focused on adenovirus and cytokine-armoring rather than selective replication.
  • Turnstone Biologics: Develops next-generation viral immunotherapies including oncolytic viruses and cancer vaccines. Adjacent peer in the engineered virus-for-cancer modality, with overlap in synthetic virology approaches to oncology.

Broad incumbents

  • Amgen (T-VEC / Imlygic): Large biopharmaceutical company with the only FDA-approved oncolytic virus therapy (talimogene laherparepvec / Imlygic for melanoma). Sets the competitive and regulatory benchmark for the engineered OV field in which Humane Genomics operates.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Humane Genomics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Humane Genomics leadership team

Management profile

Number of profiles

Profiles9 records

Humane Genomics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Humane Genomics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Humane Genomics

What does Humane Genomics do?

Humane Genomics develops engineered oncolytic RNA viruses as precision cancer therapeutics using a proprietary synthetic virology platform. Its lead candidate HGI627 is a Vesicular Stomatitis Virus engineered with two-factor authentication (GPC3-targeted glycoprotein entry plus a CTNNB1-responsive aptazyme replication ON-switch) for hepatoblastoma and pediatric liver cancer. The platform combines computer-aided virus design, a digital library of validated components, and optimized boot-up protocols to compress design-to-testable-virus timelines to under three weeks.

Is Humane Genomics a public or private company?

Humane Genomics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Humane Genomics founded?

Humane Genomics was founded in 2019. It employs 1 to 10 people.

Where is Humane Genomics based?

Humane Genomics is headquartered in New York, United States, in the North America region.

How does Humane Genomics make money?

Two revenue lines are on record. Oncolytic Viral Therapy Development and Clinical Commercialization is the primary driver. The others are platform Licensing and Partnership Deals.

Who are Humane Genomics's main competitors?

Direct peers on record are Replimune Group, Vyriad, Oncolytics Biotech, Genelux Corporation and Istari Oncology. Emerging players are TILT Biotherapeutics and Turnstone Biologics. Amgen (T-VEC / Imlygic) is listed as a broad incumbent.

Does Humane Genomics have an API?

No public API is recorded for Humane Genomics.

What industry is Humane Genomics in?

Humane Genomics's product category is Oncolytic Virotherapy / Cancer Therapeutics. Its primary akta.pro industry code is HLAAACAF, Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches), with a secondary code of HLAAACAN, Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireGenezen Announces Manufacturing Partnership with Humane Genomics to Advance Oncolytic Virus Therapy for Pediatric Liver CancerGenezen and Humane Genomics announced a manufacturing partnership to perform process transfer and cGMP manufacturing of HGI627, an oncolytic viral therapy targeting pediatric liver cancer. Under the agreement, Genezen will utilize its expertise to support the development of this novel treatment for hepatoblastoma.MatthewmandelHumane GenomicsHumane Genomics, a biotech investment by USV, has developed an oncolytic virus platform using synthetic biology to engineer viruses that selectively infect cancer cells. The platform creates a synthetic VSV virus with a two-factor authentication system, making it retargetable to different cancers and cell types. This retargetability simplifies and reduces costs for developing new drugs.Union Square VenturesHumane GenomicsAn investment was announced in Humane Genomics, a company developing synthetic oncolytic viruses to reprogram cells. The virus is designed to replicate only in cancer cells, causing them to rupture and die, with a focus on pediatric liver cancer. The company is collaborating with Texas Children's Hospital as a research partner.HumanegenomicsHumane GenomicsHumane Genomics announced Series Seed financing led by Union Square Ventures. The company has developed an oncolytic virus with 2-factor authentication that selectively kills cancer cells, targeting pediatric liver cancer. It aims to bring the therapy to clinical trials.